Strober Samuel
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5166, USA.
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10.
We have performed combined organ and hematopoietic cell transplantation using a similar conditioning regimen in mice and humans. In the mouse model of MHC-mismatched combined heart and marrow transplantation, we compared conditioning of BALB/c hosts with total lymphoid irradiation (TLI: 10 doses of 240 cGy each) targeted to the spleen, lymph nodes and thymus to conditioning with a single dose of sublethal total body irradiation (TBI; 450 cGy). Conditioning also included three injections of anti-thymocyte serum (ATS), in both groups. C57BL/6 heart grafts, marrow cells and blood mononuclear cells were transplanted 24 h after the completion of irradiation. Blood mononuclear cells were added to the marrow cells to engender severe graft versus host disease (GVHD) that is present after combined organ and hematopoietic cell transplantation in humans given non-myeloablative conditioning. Both TLI and TBI conditioned groups accepted the organ grafts and became stable chimeras. However, the TBI group all died of GVHD during the 100-day observation period. The TLI group survived during the same period without clinical signs of GVHD. These hosts were tolerized to the donor organ grafts, since third party grafts were rejected rapidly when transplanted after 100 days. When NK T-cell-deficient CD1d(-/-) BALB/c hosts were used instead of wild-type hosts in the TLI/ATS conditioned group, then all hosts survived but all rejected the organ grafts and almost all failed to develop stable chimerism. None developed GVHD. Since host NK T cells were required for graft acceptance and NK T cells are activated after recognition of CD1d on antigen presenting cells, we compared heart and marrow graft survival from wild-type versus CD1d(-/-) donors after transplantation to TLI and ATS conditioned wild-type hosts. Whereas marrow and heart grafts from wild-type donors were accepted, almost all grafts from CD1d donors were rejected. Grafts from control Jalpha18(-/-) donors that were NK T cell deficient but expressed CD1d were all accepted. The results indicate that host NK T cells facilitate graft acceptance by recognizing CD1d on donor cells. We applied the TLI conditioning regimen using 10 doses of 80 cGy each and 5 doses of rabbit ATG to human recipients of HLA-matched G-CSF "mobilized" blood mononuclear cell transplants for the treatment of leukemia and lymphoma [R. Lowsky, T. Takahashi, Y.P. Liu, et al., Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 353 (2005) 1321-1331.]. Currently more than 100 transplants have been performed, and the incidence of acute GVHD has been about 4% when both MRD and MUD transplants are combined. Almost all recipients became complete chimeras after receiving grafts that contained 2-3x10(8) CD3(+) T cells/kg. In further studies, we applied the same TLI and ATG conditioning regimen to combined kidney and G-CSF "mobilized" blood stem cell transplantation from HLA-matched sibling donors. The hematopoietic grafts in the latter protocol were selected CD34(+) cells with 1x10(6) CD3(+) T cells/kg added back to the hematopoietic cells. Preliminary results indicate that stable mixed chimerism can be achieved using this protocol allowing for complete immunosuppressive drug withdrawal without GVHD or subsequent rejection episodes. Thus, conditioning with TLI based regimens can simultaneously protect against organ graft rejection and GVHD. Levels of chimerism are dependent upon the content of donor T cells in the hematopoietic graft.
我们已在小鼠和人类中使用相似的预处理方案进行了联合器官和造血细胞移植。在 MHC 不匹配的心脏和骨髓联合移植小鼠模型中,我们将 BALB/c 宿主接受针对脾脏、淋巴结和胸腺的全淋巴照射(TLI:10 次,每次 240 cGy)的预处理与接受单次亚致死剂量全身照射(TBI;450 cGy)的预处理进行了比较。两组的预处理还都包括三次抗胸腺细胞血清(ATS)注射。在照射完成后 24 小时移植 C57BL/6 心脏移植物、骨髓细胞和血液单核细胞。将血液单核细胞添加到骨髓细胞中,以引发严重的移植物抗宿主病(GVHD),这种情况在接受非清髓性预处理的人类进行联合器官和造血细胞移植后会出现。TLI 和 TBI 预处理组均接受了器官移植物并成为稳定的嵌合体。然而,TBI 组在 100 天观察期内均死于 GVHD。TLI 组在同一时期存活,无 GVHD 的临床体征。这些宿主对供体器官移植物产生了耐受,因为在 100 天后移植第三方移植物时会迅速被排斥。当在 TLI/ATS 预处理组中使用 NK T 细胞缺陷的 CD1d(-/-) BALB/c 宿主代替野生型宿主时,所有宿主均存活,但均排斥器官移植物,几乎所有宿主都未能形成稳定的嵌合体。无一例发生 GVHD。由于宿主 NK T 细胞是移植物接受所必需的,且 NK T 细胞在识别抗原呈递细胞上的 CD1d 后被激活,我们比较了野生型与 CD1d(-/-)供体移植到 TLI 和 ATS 预处理的野生型宿主后的心脏和骨髓移植物存活情况。野生型供体的骨髓和心脏移植物被接受,而几乎所有 CD1d 供体的移植物都被排斥。来自对照 Jalpha18(-/-)供体(其 NK T 细胞缺陷但表达 CD1d)的移植物均被接受。结果表明,宿主 NK T 细胞通过识别供体细胞上的 CD1d 促进移植物接受。我们将每次 80 cGy 共 10 次剂量的 TLI 预处理方案和 5 次剂量的兔抗胸腺细胞球蛋白(ATG)应用于 HLA 匹配的 G-CSF“动员”血液单核细胞移植的白血病和淋巴瘤人类受者[R. Lowsky,T. Takahashi,Y.P. Liu 等,急性移植物抗宿主病的保护性预处理。《新英格兰医学杂志》353(2005)1321 - 1331]。目前已进行了 100 多次移植,当微小残留病(MRD)和非血缘供者(MUD)移植合并计算时,急性 GVHD 的发生率约为 4%。几乎所有受者在接受含有 2 - 3×10(8)个 CD3(+)T 细胞/kg 的移植物后都成为了完全嵌合体。在进一步研究中,我们将相同的 TLI 和 ATG 预处理方案应用于 HLA 匹配的同胞供者的联合肾脏和 G-CSF“动员”血液干细胞移植。后一方案中的造血移植物为选择的 CD34(+)细胞,并向造血细胞中回加 1×10(6)个 CD3(+)T 细胞/kg。初步结果表明,使用该方案可实现稳定的混合嵌合体,允许完全停用免疫抑制药物而无 GVHD 或随后的排斥反应。因此,基于 TLI 的预处理方案可同时预防器官移植物排斥和 GVHD。嵌合体水平取决于造血移植物中供体 T 细胞的含量。